Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study

ConclusionsThe low level of clinical activity suggests that PD-L1 inhibitor activity may be limited in R/R DLBCL.ClinicalTrials.gov IdentifierNCT02951156.

Source: Targeted Oncology - October 23, 2021 Category: Cancer & Oncology Source Type: research